Discontinued — last reported Q4 '24
Erbitux® — Revenue
Eli Lilly Erbitux® — Revenue increased by 15.1% to $175.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 16.5%, from $150.20M to $175.00M. Over 3 years (FY 2021 to FY 2024), Erbitux® — Revenue shows an upward trend with a 4.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption or successful pricing strategies for the therapy, while a decrease may signal increased competition from biosimilars or a shift in clinical treatment standards.
Detailed definition
This metric represents the total gross sales generated by the Erbitux product line within the oncology portfolio. It ref...
Peer comparison
Comparable to oncology product-specific revenue lines reported by major pharmaceutical peers, often benchmarked against the growth rates of mature biologic therapies.
lly_segment_erbitux_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $147.00M | $134.30M | $144.50M | $122.70M | $140.80M | $144.90M | $158.10M | $129.90M | $162.50M | $153.90M | $150.20M | $144.60M | $155.80M | $152.00M | $175.00M |
| QoQ Change | — | -8.6% | +7.6% | -15.1% | +14.8% | +2.9% | +9.1% | -17.8% | +25.1% | -5.3% | -2.4% | -3.7% | +7.7% | -2.4% | +15.1% |
| YoY Change | — | — | — | — | -4.2% | +7.9% | +9.4% | +5.9% | +15.4% | +6.2% | -5.0% | +11.3% | -4.1% | -1.2% | +16.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's erbitux® — revenue?
- Eli Lilly (LLY) reported erbitux® — revenue of $175.00M in Q4 2024.
- How has Eli Lilly's erbitux® — revenue changed year-over-year?
- Eli Lilly's erbitux® — revenue increased by 16.5% year-over-year, from $150.20M to $175.00M.
- What is the long-term trend for Eli Lilly's erbitux® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's erbitux® — revenue has grown at a 4.6% compound annual growth rate (CAGR), from $548.20M to $627.40M.
- What does erbitux® — revenue mean?
- The total annual sales revenue generated specifically from the Erbitux oncology product line.